Gene Expression News and Research

RSS

Gene Expression is the process by which a gene gets turned on in a cell to make RNA and proteins. Gene expression may be measured by looking at the RNA, or the protein made from the RNA, or what the protein does in a cell.

HUYA, Quintiles announce agreement to develop HBI-8000 cancer drug

HUYA Bioscience International, the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA.

29 Sep 2010

SGC releases 1000th high resolution protein structure

The Structural Genomics Consortium (SGC), an international public private partnership that aims to determine three dimensional structures of medically important proteins, announced today the release into the public domain of its 1000th high resolution protein structure.

29 Sep 2010

Researchers find genetic variants that cause arthritis in breast cancer patients taking aromatase inhibitors

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.

28 Sep 2010

Genomics obtains worldwide rights to The Garvan Institute of Medical Research's methylation DNA biomarkers

Clinical Genomics Pty. Ltd (Sydney, Australia) and The Garvan Institute of Medical Research (Sydney, Australia) today announced that they have entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the agreement, Clinical Genomics obtains worldwide exclusive rights to the Garvan's proprietary cancer associated methylation DNA biomarkers for the diagnosis and or treatment of colorectal cancer.

28 Sep 2010

GBS pathogen suppresses immune cell function in newborn infants: Research

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

27 Sep 2010

Gene alteration impacts brain tumor development: Study

The interaction between a network of altered genes appears to play an important role in the development and progression of brain tumors, according to a study in the July 15 issue of JAMA.

27 Sep 2010

Scientists discover molecular playbook to block cardiac hypertrophy

Like a well-crafted football play designed to block the opposing team's offensive drive to the end zone, the body constantly executes complex 'plays' or sequences of events to initiate, or block, different actions or functions.

24 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

New study signals hope for treatment of rare neurodegenerative disease

A new study led by St. Jude Children's Research Hospital scientists signals hope for treatment of a neurodegenerative disease and a new model for understanding the mechanism at work in other more common neurodegenerative disorders.

23 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

Study demonstrates why targeted therapies do not work in majority of people

In order for targeted therapies against cancer to be effective, scientists need to understand upfront what related proteins in a signaling "network" makes a cancer cell resistant to a drug and selectively target them as well, say researchers at Georgetown Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center.

22 Sep 2010

FDA grants orphan drug designation for MultiStem stem cell therapy

Athersys, Inc. announced today that MultiStem, Athersys' multipotent adult progenitor stem cell therapy, has been granted orphan drug designation by the U. S. Food and Drug Administration for the prevention of graft vs. host disease (GvHD).

21 Sep 2010

FDA accepts IND application for vaccine candidate based on iBioLaunch technology platform

iBio, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application filed for a vaccine candidate made with the Company's proprietary transformative technology, the iBioLaunch technology platform. The candidate vaccine was manufactured by iBio's research collaborator, Fraunhofer Center for Molecular Biotechnology (FCMB), in its cGMP pilot manufacturing facility in Newark, Delaware.

21 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.

20 Sep 2010

Penn study reveals structure of cell division's key molecule

On average, one hundred billion cells in the human body divide over the course of a day. Most of the time the body gets it right but sometimes, problems in cell replication can lead to abnormalities in chromosomes resulting in many types of disorders, from cancer to Down Syndrome.

18 Sep 2010

Researchers awarded funds to assess effects of omega-3 fatty acids on breast cancer development

Two researchers at Marshall University have been awarded federal funds totaling more than $1 million to assess the effects of omega-3 fatty acids on breast cancer development.

18 Sep 2010

Myrexis to present poster on cancer metabolism inhibitor program

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.

17 Sep 2010

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

NuGEN Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.

16 Sep 2010

Recommendations for developing novel therapies for hypertrophic cardiomyopathy

An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages.

16 Sep 2010